RDC Biomarker Study

Launched by ROYAL MARSDEN NHS FOUNDATION TRUST · May 17, 2023

Keywords

ClinConnect Summary

The RDC Biomarker Study is a clinical trial designed to help doctors quickly identify whether patients with common symptoms might have cancer. Symptoms like weight loss, fatigue, or a cough can be confusing, as only about 10% of patients referred to Rapid Diagnostic Centres actually have cancer. This study aims to develop simple blood and non-blood tests that can not only detect cancer but also identify patients who might be at higher risk of developing it in the future.

If you’re over 18 and have been referred for suspected cancer, you might be eligible to participate. Participants will provide blood, saliva, and sometimes breath samples during their first appointment and may be asked for additional samples during follow-up visits. Your personal information will remain private, as each participant will receive a unique Study ID to keep track of samples. Throughout the study, you'll also answer health-related questions to help doctors monitor your well-being. Once 1,000 patients have joined, the study will follow them for a year to gather important data for developing these new tests.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients referred to undergo investigation for suspected cancer within a non-tumour site specific RDC
• • Age \> 18 years
• Exclusion Criteria:
• • Previously treated (treatment completed within 5 years preceding recruitment)
• • Current confirmed diagnosis of active malignancy
• • Unable to or unwilling to give informed consent